Posts tagged pharmaceuticals

“Refugee children are incredibly vulnerable to developing vaccine-preventable diseases, so why do we keep hearing the players in the global vaccination community tell us these kids aren’t their problem?” asked Kate Elder, vaccines policy advisor at MSF’s Access Campaign. Read more

“Refugee children are incredibly vulnerable to developing vaccine-preventable diseases, so why do we keep hearing the players in the global vaccination community tell us these kids aren’t their problem?” asked Kate Elder, vaccines policy advisor at MSF’s Access Campaign. Read more

Countries Must Fix Critical Access to Medicines Flaws in Trans-Pacific Trade Pact

Negotiations on the Trans-Pacific Partnership (TPP)—a far-reaching trade agreement between 11 Pacific Rim countries—continue to be shrouded in secrecy, but leaked copies of the agreement reveal that the United States is demanding the most harmful package of intellectual property protections ever proposed for a trade agreement with developing countries.

These rules would make it extremely difficult for generic competitors to enter the market, keeping prices unaffordably high, with devastating public health consequences.

The Trans-Pacific Partnership (TPP): A Threat to Affordable Medicines for Millions

The TPP trade deal is currently being negotiated between the US and ten other Pacific Rim nations: Australia, Brunei Darussalam, Canada, Chile, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam. The agreement is slated to further expand its membership, potentially to all 21 Asia Pacific APEC nations. The negotiations, which began in 2010, are being conducted in secret, without the opportunity for public scrutiny. However, leaked drafts of the United States government’s proposals for some sections of the agreement reveal the inclusion of dangerous provisions that would dismantle public health safeguards enshrined in international law and restrict access to affordable generic medicines for millions of people in developing countries. To learn more visit, msfaccess.org/TPP

Dear GAVI Campaign | Vaccines: The right tools for this job? 

You know what it’s like when you don’t have the right tools for the job?

We do - because to protect children right now, we have to use vaccines that aren’t well suited to the job they have to do. We need better-adapted vaccines to reach the one in five children currently unprotected by full immunisation.

Find out more: msfaccess.org/vaccines

Indian Supreme Court Decision on Novartis Case a Victory for Access to Medicines in Developing Countries

“This is a huge relief for the millions of patients and doctors in developing countries who depend on affordable medicines from India, and for treatment providers like MSF,” said Dr. Unni Karunakara, MSF’s international president.

Test Me, Treat Me: The MSF TB Manifesto from MSF on Vimeo.

The MSF TB Manifesto: Test Me, Treat Me

The last TB drug was created in the 60’s. That means that for the past 50 years, TB has developed drug resistance, and continues to spread without new medicines for treatment. It is time to demand more, and demand better treatment for drug-resistant TB. 

MSF’s patients and staff are calling for: universal access to diagnosis and treatment for drug-resistant TB, research to find shorter, less toxic and more effective treatments, and funding to increase care and research.

Photo: A young patient in Tajikistan. Tajikistan 2012 © Natasha Sergeeva/MSF
First New TB Drug In 50 Years Approved Must Be Made Widely Available
The approval by the US Food and Drug Administration of an important new tuberculosis treatment must lead to its availability in countries with high levels of the drug-resistant form of the deadly disease, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) said today.
The new drug, bedaquiline, is the first active agent against tuberculosis to be registered since 1963, and its approval was welcomed by MSF as it marks a major improvement in combating the most challenging forms of TB, which require complex regimes often accompanied by pronounced side effects.
“The first new drug to treat TB in 50 years is an immense milestone,” said Dr. Manica Balasegaram, executive director of the MSF Access Campaign. “The fact that the drug is active against drug-resistant forms of the disease makes it a potential game changer.”

Photo: A young patient in Tajikistan. Tajikistan 2012 © Natasha Sergeeva/MSF

First New TB Drug In 50 Years Approved Must Be Made Widely Available

The approval by the US Food and Drug Administration of an important new tuberculosis treatment must lead to its availability in countries with high levels of the drug-resistant form of the deadly disease, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) said today.

The new drug, bedaquiline, is the first active agent against tuberculosis to be registered since 1963, and its approval was welcomed by MSF as it marks a major improvement in combating the most challenging forms of TB, which require complex regimes often accompanied by pronounced side effects.

“The first new drug to treat TB in 50 years is an immense milestone,” said Dr. Manica Balasegaram, executive director of the MSF Access Campaign. “The fact that the drug is active against drug-resistant forms of the disease makes it a potential game changer.”

Photo: Paraguay © Anna Surinyach
Fighting Neglect
MSFhas taken a stand for the millions of people affected by visceral leishmaniasis, sleeping sickness and Chagas. These diseases are neglected by drug developers, policy makers, and media, making it difficult to get patients the treatment they need. Treatment is possible with the existing medical tools and drugs, but additional research and development toward new and more effective diagnostics and treatments are desperately needed to address the overwhelming neglect of people whose needs are not met by pharmaceutical companies.
Learn more about neglected tropical diseases (NTDs) in our Special Report.

Photo: Paraguay © Anna Surinyach

Fighting Neglect

MSFhas taken a stand for the millions of people affected by visceral leishmaniasis, sleeping sickness and Chagas. These diseases are neglected by drug developers, policy makers, and media, making it difficult to get patients the treatment they need. Treatment is possible with the existing medical tools and drugs, but additional research and development toward new and more effective diagnostics and treatments are desperately needed to address the overwhelming neglect of people whose needs are not met by pharmaceutical companies.


Learn more about neglected tropical diseases (NTDs) in our Special Report.

Bayer Attempting To Block Affordable Patented Drugs In India

German pharmaceutical company Bayer is challenging an intellectual property decision in India that allows more affordable generic drugs to be produced in the interests of public health. You can see the extent of the price differences in this image. 

Learn more about the case. 

Graphic by Will Owen

Bayer Attempting To Block Affordable Patented Drugs In India

German pharmaceutical company Bayer is challenging an intellectual property decision in India that allows more affordable generic drugs to be produced in the interests of public health. You can see the extent of the price differences in this image.

Learn more about the case.

Graphic by Will Owen

Last week, MSF joined thousands of protesters at the International AIDS Conference in Washington D.C., calling for governments and pharmaceutical companies to halt policies and practices that undermine access to medicines. Watch this video to hear protestors tell in their own voices why they marched.

Tuesday, MSF marched in the streets of DC with other organizations at the Internetional AIDS Conference. We told pharma to put people before profits. Millions die without access to affordable generic meds, we marched and will continue to march for them.

Tuesday, MSF marched in the streets of DC with other organizations at the Internetional AIDS Conference. We told pharma to put people before profits. Millions die without access to affordable generic meds, we marched and will continue to march for them.

Fighting Neglect: Chagas:

Chagas is a parasitic disease found on the American continent, where it affects an estimated 8 to 10 million people and claims up to 12,500 lives every year.

Learn more about Chagas and other neglected diseases.

DNDi and New Drugs for Neglected Diseases

Founded in 2003, the Drugs for Neglected Diseases initiative (DNDi) brings together the academic, medical, public health, and pharmaceutical worlds to create effective drugs to treat neglected diseases like Chagas disease, sleeping sickness, and visceral leishmaniasis. DNDi has developed an innovative not-for-profit model for drug research and development that is patient-centered and based on needs rather than profits. 

in 2003 MSF brought together five prominent public sector research institutes—Brazil’s Oswaldo Cruz Foundation, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia, and France’s Pasteur Institute—and the UNDP/World Bank/World Health Organization’s Special Program for Research and Training in Tropical Diseases to create DNDi.

In just seven years, under the leadership of former General Director of MSF in France, Dr. Bernard Pecoul, DNDi has introduced six new treatments: two treatments for drug-resistant malaria that have already reached 150 million people; the first new treatment in 25 years for the advanced stage of sleeping sickness; for visceral leishmaniasis, a new combination therapy for patients in Africa and a set of combination therapies for patients in South Asia; and a new child-adapted Chagas disease drug formulation.
Photo: Screening for Chagas in Colombia.
Colombia 2010 © Mads Nissen

DNDi and New Drugs for Neglected Diseases

Founded in 2003, the Drugs for Neglected Diseases initiative (DNDi) brings together the academic, medical, public health, and pharmaceutical worlds to create effective drugs to treat neglected diseases like Chagas disease, sleeping sickness, and visceral leishmaniasis. DNDi has developed an innovative not-for-profit model for drug research and development that is patient-centered and based on needs rather than profits.

in 2003 MSF brought together five prominent public sector research institutes—Brazil’s Oswaldo Cruz Foundation, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia, and France’s Pasteur Institute—and the UNDP/World Bank/World Health Organization’s Special Program for Research and Training in Tropical Diseases to create DNDi.

In just seven years, under the leadership of former General Director of MSF in France, Dr. Bernard Pecoul, DNDi has introduced six new treatments: two treatments for drug-resistant malaria that have already reached 150 million people; the first new treatment in 25 years for the advanced stage of sleeping sickness; for visceral leishmaniasis, a new combination therapy for patients in Africa and a set of combination therapies for patients in South Asia; and a new child-adapted Chagas disease drug formulation.

Photo: Screening for Chagas in Colombia.
Colombia 2010 © Mads Nissen

Leaving people without drugs is like tying a rope round a person’s neck

Charles

Charles, a Kenyan who benefits from access to vital medications that are at risk of being cut off.

Join in on the action and tweet this line:

Help #MSF protect access to affordable meds, tell @Novartis to drop its case vs #India http://ow.ly/8XPoQ #STOPnovartis

More about the situation in India regarding the law suit with Novartis and what actions YOU can take!

CALL TO ACTION!

novartisWe need YOU to help us #StopNovartis!

For the past 6 years drug giant Novartis has been pursuing a legal case in India that threatens access to life-saving affordable medicines for millions across the developing world.

As the case now opens before the Indian Supreme Court, join MSF & tell Novartis that people matter more than profits.

Join in on the action and tweet this line:

Help #MSF protect access to affordable meds, tell @Novartis to drop its case vs #India http://ow.ly/8XPoQ #STOPnovartis

For more information about the case and what actions you can take go here.